Previous Article | Next Article 
Journal of Virology, January 2001, p. 362-374, Vol. 75, No. 1
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.1.362-374.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Functional Analysis of the Simian Immunodeficiency
Virus Vpx Protein: Identification of Packaging Determinants and a
Novel Nuclear Targeting Domain
Sundarasamy
Mahalingam,1,
Brian
Van
Tine,1
Mario L.
Santiago,2
Feng
Gao,1
George M.
Shaw,1,2,3 and
Beatrice H.
Hahn1,2,*
Departments of
Medicine1 and
Microbiology2 and Howard Hughes
Medical Institute,3 University of Alabama at
Birmingham, Birmingham, Alabama 35294
Received 24 July 2000/Accepted 9 October 2000
 |
ABSTRACT |
The vpx gene products of human immunodeficiency virus
type 2 (HIV-2) and of the closely related simian immunodeficiency
viruses from sooty mangabeys (SIVsm) and macaques (SIVmac) comprise a 112-amino-acid virion-associated protein that is critical for efficient
virus replication in nondividing cells such as macrophages. When
expressed in the absence of other viral proteins, Vpx localizes to the
nuclear membrane as well as to the nucleus; however, in the context of
virus replication Vpx is packaged into virions via interaction with the
p6 domain of the Gag precursor polyprotein (p55gag). To identify the domains essential for
virion incorporation and nuclear localization, site-directed mutations
were introduced into the vpx gene of SIVsmPBj1.9 and
functionally analyzed. Our results show that (i) mutation of two highly
conserved L74 and I75 residues impaired both virion incorporation and
nuclear localization of Vpx; (ii) substitution of conserved H82, G86,
C87, P103, and P106 residues impaired Vpx nuclear localization but not
virion incorporation; (iii) mutations of conserved Y66, Y69, and Y71 residues impaired virion incorporation but not the translocation of Vpx
to the nucleus; and (iv) a mutation at E30 (predicted to disrupt an
N-terminal
-helix) had no effect on either virion incorporation or
nuclear localization of Vpx. Importantly, mutations in Vpx which
impaired nuclear localization also reduced virus replication in macaque
macrophages, suggesting an important role of the carboxyl terminus of
Vpx in nuclear translocation of the viral preintegration complex.
Analyzing this domain in greater detail, we identified a 26-amino-acid
(aa 60 to 85) fragment that was sufficient to mediate the transport of
a heterologous protein (green fluorescent protein [GFP]) to the
nucleus. Taken together, these results indicate that virion
incorporation and nuclear localization are encoded by two partially
overlapping domains in the C-terminus of Vpx (aa 60 to 112). The
identification of a novel 26-amino-acid nuclear targeting domain
provides a new tool to investigate the nuclear import of the HIV-2/SIV
preintegration complex.
 |
INTRODUCTION |
One of the features that
distinguishes lentiviruses from oncoretroviruses is their genetic
complexity. Human immunodeficiency virus types 1 and 2 (HIV-1 and
HIV-2, respectively), and the various simian immunodeficiency viruses
(SIVs) which naturally infect more than 20 nonhuman primate species
(26) encode several accessory and/or regulatory genes in
addition to the structural gag, pol, and
env genes that are present in all retroviruses (7,
69). An important step in the early stages of the retrovirus
life cycle is the nuclear import of the viral preintegration complex
(PIC), a prerequisite for integration of viral DNA into the host genome (4, 11, 17). While nuclear import and integration of
oncoretroviral DNA requires breakdown of the nuclear membrane during
mitosis, lentiviruses are able to infect nondividing host cells by
exploiting cellular nuclear import pathways (37). In the
case of HIV-1, the p17 Gag matrix (4, 19), the integrase
(17), and Vpr (28, 59, 72) have been
implicated as mediators of PIC nuclear translocation, although there is
controversy concerning the role of the matrix in this process
(14). The matrix and integrase contain classical nuclear
localization signals (NLSs) and bind to importin
and importin
for transport to and across the nuclear envelope (4, 18,
59). By contrast, Vpr is believed to contribute to nuclear
targeting of the viral PIC by exploiting nonclassical pathways
(31). Two discrete Vpr nuclear localization domains have
been reported that seem to interact with both proximal and distal
components of the nuclear import pathway (31). Vpr has also been shown to bind directly to nucleoporin proteins and to colocalize with importin
in the nuclear membrane, suggesting that
it is involved in the docking of the viral PIC to the nuclear pore
complex (NPC) (13).
HIV-1 Vpr localizes to the nucleus (9, 31, 40) and the
nuclear membrane (13, 41, 72) when expressed in the
absence of other viral proteins. Mutational analyses have indicated
that two
-helical domains, one each in the N and C termini, and a third arginine-rich domain at the C terminus are all critical for this
function (9, 41, 42, 66, 75, 77, 78). Moreover, the
-helical domains are also essential for virion incorporation of Vpr
(42, 75). Vpr causes arrest of eukaryotic cells at the
G2 stage of the cell cycle (9, 40, 41, 61, 62). This property of Vpr has been mapped to amino acid
positions 71 to 82 (9, 40, 41) and may serve to enhance
viral gene expression since the HIV-1 long terminal repeat is more
active during the G2 phase of the cell cycle
(22).
Viruses in the HIV-2/SIVsm/SIVmac lineage contain a vpr gene
as well as an evolutionarily related vpx gene. A recent
report from our group demonstrated that SIVsm Vpr and Vpx proteins have distinct and noncomplementary functions (12). Vpr induces
cell cycle arrest at the G2 stage (12, 65),
whereas Vpx is involved in the nuclear import of the viral PIC
(12, 54). Vpx is an 18-kDa, 112-amino-acid protein which
is highly conserved among divergent isolates of HIV-2 and SIVsm
(29, 33, 76). Vpx mutant SIVsm is significantly reduced in
its ability to replicate in macaque macrophages (12). Vpx
is also essential for efficient in vivo dissemination and spread of
SIVsm following mucosal and intravenous infection of macaques
(30). Vpx is packaged into virus particles (29, 33,
74, 76) and present in PICs (12). Within viral
particles, Vpx seems to be localized within the viral core
(35). Virion incorporation is mediated by the p6 domain of
the Gag precursor polyprotein, p55gag (1,
53). Vpx has also been shown to bind to single-stranded nucleic
acids, although the biological relevance of this finding is presently
unclear (29).
Despite its requirement for HIV-2/SIVsm replication in nondividing
cells in vitro and in vivo, systematic structure-function analyses of
the Vpx protein have not been reported. Two previous studies showed
that deletion of amino acid residues 78 to 80, 82 to 87, and 73 to 89 abolished the incorporation of Vpx into virus particles (53,
55). However, it remains unclear whether this was due to altered
stability and/or structural conformation of the mutant Vpx proteins.
Also, the mechanism by which Vpx mediates the nuclear import of
HIV-2/SIVsm PICs remains unknown. Immunofluorescence studies have shown
that Vpx localizes to the plasma membrane in cells infected with
HIV-2/SIVsm (34) but that, when it is expressed in the
absence of other viral proteins, it localizes to the nuclear membrane
as well as inside the nucleus (72). More recently, Pancio
and coworkers reported that deletion of the proline-rich C terminus of
the HIV-2/ROD Vpx protein (carboxyl-terminal 11 amino acids) abrogated
its nuclear localization function and attenuated HIV-2 replication in
macrophages (54).
Determining how Vpx enters the nucleus is important to ultimately
understand its function within in the context of the viral PIC.
Proteins that exceed the 40-kDa diffusion limit of the NPC must be
actively imported via specific pathways following the recognition of
cis-acting targeting sequences, termed NLSs (23, 24,
50). A number of distinct pathways of protein nuclear import
have been described. The most extensively characterized is the
classical pathway which utilizes monopartite (short stretch of basic
residues)- or bipartite (two stretches of basic residues connected by a
short linker)-type NLSs (10). These NLSs first interact in
the cytoplasm with the import receptors, importin
and importin
,
and then dock at saturable sites on the cytoplasmic face of the nuclear
pore via importin
(6, 10, 24, 25, 43, 44, 48, 50, 51).
The importins and their cargo then translocate through the pore for
delivery to the nuclear interior. However, a number of NLSs which do
not conform to these consensus sequences have also been described
(31, 36, 47, 50). For example, transportin (an importin
-like receptor) recognizes a 38-amino-acid glycine-rich sequence
termed M9 and transports a subset of heterogeneous nuclear
ribonucleoproteins (hnRNPs) (2, 15, 58, 60). Importin
also directly recognizes arginine-rich NLSs and transports the HIV
regulatory proteins Tat and Rev to the nucleus without an importin
intermediate (52, 70). Vpx does not contain sequence
elements homologous to any of the previously characterized NLS domains,
and it is thus possible that it contains a novel NLS. Alternatively,
Vpx may gain access to the nucleus by interacting with another
NLS-containing protein.
In this study, we report a systematic mutational analysis of the
SIVsm(PBj1.9) vpx gene and present functional data for
wild-type and mutant Vpx proteins as well as Vpx-encoding proviral
constructs. We confirm that Vpx localizes to the nuclear membrane and
the nucleus in mammalian cells when expressed alone or in the context of a green fluorescent protein (GFP) fusion protein. We also describe point mutants of Vpx that segregate virion incorporation and nuclear localization functions. Finally, we describe a highly conserved protein
domain (amino acids [aa] 60 to 85) within the carboxyl terminus of
Vpx that is sufficient to mediate the transport of a heterologous
protein (GFP) to the nucleus.
 |
MATERIALS AND METHODS |
Construction of SIVsm(PBj1.9) Vpx mutant proviruses and
expression vectors.
Mutational analyses were performed using the
infectious molecular clone SIVsm(PBj1.9) (8). The
quick-change site-directed mutagenesis kit (Stratagene, La Jolla,
Calif.) was used to introduce mutations into the PBj1.9 vpx
gene (subcloned as an internal SpeI-ClaI DNA
fragment). The primers used for the generation of different PBj1.9
vpx mutants were as follows: for VpxE30P,
3'-GACAGAACAGTACCAGAAATAAACAGG-5' (forward) and
3'-CCTGTTTATTTCTGGTACTGTTCTGTC-5' (reverse); for VpxY66,69,71A,
3'-GGGATG TCAGTCAGCGCCACTAAAGCCAGAGCCTTGTGCTTGATACAG-5' (forward)
and 3'-CTGTATCAAGCACAAGGCTCTGGCTTTAGTGGCGCTGACTGACATCCC-5' (reverse); for VpxLI74,75S,
3'-CACTAAATACAGATACTTGTGCTCCTCACAGAAAGCTATGTTTATGC-5' (forward) and
3'-GC ATAAACATAGCTTTCTGTGAGGAGCACAAGTATCTGTATTTAGTG-5' (reverse);
for VpxH82S, 3'-CAGAAAGCTATGTTTATGTCTTGCAAGAAAGGGTGTAGG-5' (forward) and
3'-CCTACACCCTTTCTTGCAAGACATAAACATAGCTTTCTG-5'
(reverse); for VpxGC86,87S,
3'-GTTTATGCATTGCAAGAAATCGTCAAGGTGCTTAGGAGGAGAGC-5' (forward) and
3'- GCTCTCCTCCTAAGCACCTTGACGATTTCTTGCAATGCATAAAC-5' (reverse);
and for Vpx P103,106S,
3'-GCATGGGGCAGGGGGATGGAGACCAGGGTCTCCTCCTTCTCCCCCTCCAGGACTAGC-5' (forward) and
3'-G CTAGTCCTGGAGGGGGAGAAGGAGGAGACCCTGGTCTCCATCCCC CTGCCCCATGC-5'
(reverse). Mutagenized vpx genes were reinserted into
the PBj1.9 proviral vector using a series of subcloning steps. None of
the introduced nucleotide substitutions resulted in amino acid changes
in overlapping Vif open reading frames. Wild-type and different mutant
Vpx expression constructs were generated by inserting PCR-amplified
vpx gene fragments (Vpx-BamH
[forward; 3'-AATCTCGGATCCGCCGCCACCATGTCAGATCCCAGGGAGAGAAT C-5']
and Vpx-Xho [reverse;
3'-TAGAATCTCGAGTTATGCTAGTCCTGGAGGGGGAGG-5']) into the mammalian expression vector pCDNA3 (Invitrogen, Carlsbad, Calif.). All
introduced mutations were confirmed by DNA sequence analysis.
Construction of Vpx-GFP fusion proteins.
To generate Vpx-GFP
fusion constructs, the entire Vpx coding region and three Vpx fragments
(Vpx1-63, Vpx64-112, and Vpx60-85) were fused to the carboxyl terminus
of GFP and then cloned into the mammalian expression vector pCDNA3.
GFP-Vpx fusion constructs were generated by overlap PCR using the
following primers: for GFP
3'-CATCTAAAGCTTACCGCCGCCACCATGGTGAGCAAGGGCGAGGAG-5'
(forward) and 3'-CATCTACTCGAGTTACTTGTACAGCTCGTCCAT-5'
(reverse); for GFP-Vpx 3'-ATGGACGAGCTGTACAAGTCCGGACTCAGAATGTCAGATCCCAGGGAGAGAAT-5'
(forward) and 3'-GAGTCCGGACTTGTACAGCTCGTCCATGCC-5'
(reverse); for GFP-Vpx64-112, 3'-ATGGACG AGCTGTACAAGTCCGGACTCAGAGTCAGCTACACTAAATACAGA-5' (forward); and for GFP-Vpx60-85
3'-TAGAATCTCGAGTTATTTCTTGCAA TGCATAAACATAGCTTTCTGTATCAAGCACAAGTATCTGTATTTAGT GTAGCTGACTGACATCCCCATGGAGCCGCCCTTGTACAGCTCGTCC ATGCCGA-5'
(reverse). All fusion constructs were confirmed by DNA sequence analysis.
Cell culture.
CEMx174 cells were maintained in RPMI 1640 supplemented with 2 mM L-glutamine, penicillin (100 U/ml),
streptomycin (100 µg/ml), and 10% fetal bovine serum (FBS). 293T and
HeLa cells were maintained in Dulbecco's modified Eagle's medium
supplemented with penicillin (100 U/ml), streptomycin (100 µg/ml),
and 10% FBS. Macaque peripheral blood mononuclear cells (PBMCs) were
obtained from heparin-treated whole blood using lymphocyte separation
medium (Organon Teknika, Durham, N.C.), stimulated with
phytohemagglutinin (4 µg/ml) for 2 to 3 days, and maintained in
medium supplemented with interleukin 2 (10 U/ml). Macrophages were
purified from unstimulated macaque PBMCs by adherence to plastic as
described previously (12). Briefly, 3 × 106 macaque PBMCs were placed in 12-well tissue culture
plates in macrophage medium containing 10% autologous macaque serum
and conditioned medium to supply growth factors (12).
Nonadherent cells were removed after 30 to 60 min of incubation at
37°C, followed by extensive washing with phosphate-buffered saline
(PBS). Cells were allowed to differentiate in macrophage medium for 10 to 12 days prior to virus infection.
Transfection and infection.
For the generation of virus
stocks, 293T cells were transfected with wild-type and vpx
mutant SIVsm(PBj1.9) proviral DNAs (10 µg) using an MBS mammalian
transfection kit (Stratagene, La Jolla, Calif.). Forty-eight hours
after transfection, cell culture supernatants were collected,
clarified by low-speed centrifugation (1,000 × g, 10 min), and analyzed for core antigen
(p27gag) content using an SIV core antigen assay
(Coulter, Miami, Fla.). CEMx174 and macaque PBMCs were then infected
with supernatants containing 10 ng of p27gag,
incubated overnight at 37°C in 5% CO2; this incubation
was followed by extensive washing to remove residual virus. Infected
cells were resuspended in 10 ml of complete T-cell medium (supplemented with 30 U of interleukin-2 per ml). Culture supernatants were split 1:2
every 3 days with fresh medium and aliquots of culture supernatants
were frozen at
70°C for p27gag
determinations at the conclusion of the experiments. Terminally differentiated macaque macrophages were infected with virion
preparations containing 10 ng of p27gag in
12-well plates overnight at 37°C in 5% CO2 and then
washed extensively to remove residual virus. Infected cells were
adjusted to 2 ml with macrophage medium and incubated at 37°C.
Culture supernatant was collected at 3-day intervals and frozen at
70°C for p27gag determinations. For virus
rescue experiments, medium was removed at day 21 postinfection and
macrophages were cocultivated with 1 × 106 CEMx174
cells in the appropriate medium for 24 h. Nonadherent cells were
transferred to T25 tissue culture flasks and incubated for an
additional 21 days. Culture supernatants were collected at 3-day
intervals for p27gag determinations.
Western blot analysis.
Culture supernatants from transfected
cells were clarified of cellular debris by low-speed centrifugation
(1,000 × g, 10 min). Virions were then concentrated by
ultracentrifugation (125,000 × g, 2 h) through a
20% sucrose cushion, and viral pellets were solubilized in loading
buffer (62.5 mM Tris-HCl [pH 6.8], 0.2% sodium dodecyl sulfate
[SDS], 5% 2-mercaptoethanol, 10% glycerol). Viral samples were
denatured by boiling and separated on a 15% polyacrylamide gel
containing SDS. Following electrophoresis, proteins were transferred to
a Hybond ECL nitrocellulose membrane (Amersham Pharmacia, Piscataway,
N.J.) by electroblotting, incubated overnight at 4°C in blocking
buffer (5% nonfat dry milk in PBS) and then for 2 h at room
temperature with the appropriate antibodies, diluted in blocking
buffer. Anti-Vpx and anti-Gag monoclonal antibodies were used at
dilutions of 1:500 and 1:1,000, respectively (the properties of these
antibodies are described in reference 74)). Protein-bound antibodies were probed with horseradish
peroxidase-conjugated specific secondary antibodies (at a 1:1,000
dilution), washed extensively, and developed using the enhanced
chemiluminescence detection system (Amersham Pharmacia).
Fluorescence microscopy.
HeLa cells were maintained in
Dulbecco's modified Eagle's medium containing 10% FBS, seeded onto
Falcon Chamber culture slides (Becton Dickinson, San Diego, Calif.),
and transfected with Vpx expression plasmids using Superfect (Qiagen,
Santa Clarita, Calif.) according to manufacturer's instructions.
Twenty-four to 48 h after transfection, the cells were washed with
PBS, fixed with 4% paraformaldehyde-PBS at room temperature for 10 min, and probed with the monoclonal anti-Vpx (74) antibody
(1:200) for 90 min at 37°C. Fluorescein isothiocyanate
(FITC)-conjugated affinity-purified goat anti-mouse immunoglobulin G
(Sigma, St. Louis, Mo.) was used as a secondary antibody to visualize
the subcellular localization of Vpx. Texas red-phalloidin was used to
stain cytoplasmic actin, and 4,6-diamidino-2-phenylindole (DAPI) was
used to stain nuclei (Sigma). To determine the subcellular localization
of the GFP-Vpx fusion proteins, cells were fixed with 4%
paraformaldehyde for 10 min after transfection and then stained with a
rabbit polyclonal antibody specific for the nucleoporin protein p62
(Becton-Dickinson Transduction Laboratories, San Diego, Calif.). Bound
antibodies were detected with a Texas red-conjugated goat anti-rabbit
secondary antibody, and DAPI was used for nuclear staining. Samples
were viewed with an upright Nikon E800 microscope and photographed with
a photometrics charge-coupled device camera using Metamorph software.
 |
RESULTS |
Construction of mutant vpx genes.
For functional
analyses of Vpx, we introduced point mutations into the vpx
gene of the infectious molecular clone SIVsm(PBj1.9) as a
representative of the HIV-2/SIVsm group of viruses (8). This clone has a complete set of uninterrupted accessory genes, replicates well in macaque macrophages, and represents a primary (PBMC-derived) SIVsm isolate. Protein domains conserved among the
vpx gene products of highly divergent HIV-2 and SIV isolates were targeted for mutagenesis. Such domains were identified by aligning
the deduced Vpx amino acid sequences of available HIV-1 and
SIVsm/SIVmac isolates with the Vpx protein sequence of SIVrcm (Fig.
1A), a highly divergent SIV identified
only recently to naturally infect red-capped mangabeys
(21, 26; F. Gao, E. Bailes, Y. Li, J. Decker, Y. Chen, F. Simon, E. Nerrienet, S. Souquiere, P. A. Marx,
P. Sharp, and B. H. Hahn, Keystone Symposia: novel biological
approaches to HIV-1 infeciton based on new insights into HIV biology,
abstr. 311, 2000). We also targeted two putative
-helices located
between amino acid residues 18 and 49 and 71 and 82, respectively, and
introduced amino acid residues that would be predicted to disrupt these
structures (Fig. 2). A glutamic acid
residue at position 30 in the putative helical domain I (aa 18 to 49)
was substituted with a proline residue (E30P) known to have a low
potential for supporting
-helical structures (5, 67).
Similarly, three conserved tyrosine residues in the putative helical
domain II (aa 71 to 82) were replaced with nonpolar alanines (Y66,69,71A), and a leucine and an isoleucine residue were exchanged with serines (LI74,75S) to introduce structural as well as
hydrophobic modifications. A conserved histidine residue at position 82 and glycine and cysteine residues at positions 86 and 87, respectively, were also exchanged with serines (H82S and GC86,87S). All but one of
these residues are also known to be conserved in the Vpr protein of
HIV-1 (Fig. 1B) and have been shown to be important for this protein's
virion incorporation and nuclear localization functions (41, 56,
77). Finally, proline-rich motifs have been shown to mediate
protein-protein interactions in a wide range of cellular proteins with
unrelated functions and have been implicated in viral budding and
assembly processes (20, 27). Although the Vpx protein
sequence of SIVrcm lacks a proline-rich C terminus (confirmed by
analyzing two independent SIVrcm isolates [data not shown]), we
replaced two proline residues with serine residues (P103,106S) at the
carboxyl terminus of the PBj1.9 Vpx (Fig. 2).

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 1.
(A) Alignment of deduced Vpx protein sequences from
divergent HIV-2 and SIV isolates. Sequences are compared to the
SIVsm(PBj1.9) Vpx protein sequence. Dots indicate amino acid
sequence identity. Dashes represent gaps inserted to improve the
alignment. The HIV-2/SIV Vpx sequences shown were obtained from the Los
Alamos HIV sequence database (http://hiv-web.lanl.gov/), except for the
deduced Vpx protein sequence of SIVrcm(GB1), which is unpublished. (B)
Alignment of Vpx [SIVsm(PBj1.9)] and Vpr [HIV-1(89.6)] protein
sequences. Groups of amino acid residues chosen for mutagenesis are
highlighted in color.
|
|

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 2.
Construction of SIVsm(PBj1.9) vpx mutant
proviruses. The genetic organization of the SIVsm(PBj1.9) genome is
shown at the top, with Vpx substitution mutations indicated at the
bottom. None of the amino acid substitutions altered the coding
sequences of the overlapping Vif open reading frames.
|
|
Effects of mutations on expression and packaging of Vpx.
To
study the effect of the site-directed Vpx mutations on the expression
of this protein in mammalian cells, we employed a vaccinia virus
T7-RNA polymerase system (16). vTF7-3-infected HeLa cells
were transfected with wild-type or mutant Vpx plasmids, and expression
was driven by the bacteriophage T7 promoter. Transfected cells were
labeled with 35S, lysed, immunoprecipitated with an
anti-Vpx antiserum, and analyzed by SDS-polyacrylamide gel
electrophoresis. As expected, cells transfected with plasmids
containing wild-type Vpx expressed an 18-kDa protein (Fig. 3A, lane
1). This was also the case for cells transfected with all of the mutant Vpx plasmids (Fig. 3A, lanes 3 to
8). X2, a mutant in which the initiating and internal methionine codons
were replaced with threonine and leucine residues and which contained a
stop codon at amino acid position 80 (12), was used as a negative control (Fig. 3A, lane 2).

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 3.
Expression and virion incorporation of mutant Vpx
proteins. (A) vTF7-3 infected HeLa cells were transfected with Vpx
expression plasmids. Transfected cells were labeled with
35S and the cell-associated Vpx proteins were
immunoprecipitated with a Vpx-specific monoclonal antiserum. Lane 1, wild-type (Wt); lane 2, X2 (a control construct lacking a functional
vpx open reading frame) (12); lanes 3 to 8, mutant constructs, as indicated above lanes. (B) Western blot analysis
of SIVsm(PBj1.9) viral particles containing mutant Vpx proteins. 293T
cells were transfected with vpx mutant PBj1.9 proviral
clones. Virus particles were concentrated from culture supernatants by
ultracentrifugation through a 20% sucrose cushion, solubilized in gel
loading buffer, and analyzed for protein content by Western blot
analysis using Gag (upper panel)- and Vpx (lower panel)-specific
antibodies. Lane 1, wild type (Wt); lane 2, negative control (see
legend for panel A); lanes 3 to 8, mutant constructs, as indicated
above lanes.
|
|
We next tested the various mutant Vpx proteins for their ability to
package into virions. Mutant
vpx genes were introduced
back
into the SIVsm(PBj1.9) provirus and then transfected into
293T cells.
Cell culture supernatants were collected 48 h after
transfection
and centrifuged over a 20% sucrose cushion, and the
viral pellets
(normalized by p27
gag content) were examined by
Western blot analysis (Fig.
3B). Probing
with an anti-Gag monoclonal
antibody (
74) showed that the expression,
processing, and
assembly of Gag was not affected by the various
vpx
mutations (Fig.
3B, upper portion). However, probing with
a
Vpx-specific antiserum revealed the absence of Vpx from two
mutants
(Y66,69,71A and LI74,75S) (Fig.
3B, lanes 4 and 5). Interestingly,
the
E30P mutation did not abrogate Vpx packaging, suggesting that
the
N-terminal

-helix is dispensable for virion incorporation.
This was
also true for mutations in the carboxyl-terminal region
(aa 82 to 112).
However, the highly conserved tyrosine residues
at positions 66, 69, and 71, as well as the leucine and isoleucine
residues at positions 74 and 75, were clearly identified to be
critical for Vpx assembly into
virus
particles.
Carboxyl terminus of Vpx is required for productive macrophage
infection.
Vpx is essential for efficient HIV-2/SIVsm replication
in nondividing cells (12, 54). To map the domains of
Vpx involved in this process, we examined the ability of wild-type
and mutant SIVsm(PBj1.9) constructs to elicit a spreading
infection in monocyte-derived macaque macrophages. All vpx
mutant viruses replicated efficiently and to high titers in CEMx174
cells and macaque PBMCs (Fig. 4A and B).
However, this was not the case in terminally differentiated macaque
macrophage cultures (Fig. 4C). As expected, PBj1.9 mutants that failed
to package Vpx proteins were severely impaired in their ability to
replicate in macrophages. However, failure to replicate in macrophages
was also observed for mutants that were packaged into virus particles
at near wild-type quantities: these included H82S, GC86,87S, and
P103,106S. In three independent experiments, PBj1.9 mutants with
substitution in the carboxyl-terminal half of Vpx replicated poorly in
macrophages, while the E30P mutation designed to disrupt the predicted
N-terminal
-helix resulted in a growth pattern virtually identical
to that of wild-type virus (Fig. 4C). Interestingly, among the Vpx
mutants that did package, H82S replicated most poorly in macrophages.
The other two constructs, GC86,87S and P103,106S, exhibited some
residual replication capacity compared to the X2 control (Fig.
4C). Consistent with previous findings (12), all Vpx
mutants were rescued by CEMx174 cocultivation after 21 days (Fig. 4C),
indicating persistent low-level infection in macrophage cultures even
in the absence of a functional Vpx.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 4.
Replication kinetics of wild-type and vpx
mutant PBj1.9 proviruses. CEMx174 cells (A), macaque PBMCs (B), and
terminally differentiated macaque macrophages (C) were infected with
the indicated SIVsm(PBj1.9) virus constructs equilibrated by
p27gag content (10 ng of
p27gag per 106 cells). The isolation
and infection of primary macaque PBMCs and macrophages are described in
Materials and Methods. Virus replication was assessed by quantifying
the amounts of p27gag antigen in culture
supernatants at 3-day intervals postinfection. Twenty-one days after
infection, adherent macrophages were cocultured for 24 h with
1 × 106 CEMx174 cells. Nonadherent cells were removed
and analyzed at 3-day intervals for p27gag
antigen production. wt, wild type; X2, negative control.
|
|
Subcellular localization of Vpx.
To characterize further the
loss-of-function mutants, we determined the subcellular localization of
all Vpx proteins using an indirect immunofluorescence assay. HeLa cells
were transfected with the wild-type Vpx expression plasmid, fixed with
paraformaldehyde, and then stained with an anti-Vpx antiserum
(74). As reported previously (72), wild-type
Vpx localized primarily to the inside of the nuclear membrane in
transfected cells (Fig.
5, top row. The
specificity of this staining was demonstrated by the absence of a
signal in mock-transfected cells (data not shown). Vpx E30P and
Y66,69,71A mutants exhibited a subcellular localization very similar to
that of wild-type Vpx although their nuclear staining pattern was
punctate (Fig. 5, rows 2 and 3). By contrast, LI74,75S and H82S mutants
resulted in a complete loss of nuclear staining, with mutant Vpx
proteins detected exclusively in the cytoplasm (Fig. 5, rows 4 and 5).
Still another pattern was observed for GC86,87S and P103,106S, which
accumulated both in the nucleus and in the cytoplasm (Fig. 5, rows
6 and 7). Although there was some nuclear staining, the diffuse pattern
observed for these two Vpx mutants strongly suggested that nuclear
import had been perturbed. Of note, there was considerable variation
between individual cells in the intensity of fluorescence staining but
no obvious correlation between the level of intensity and the patterns
of subcellular localization. Taken together, these results along with
the replication data in macrophages strongly suggested that a domain in
the carboxyl terminus of Vpx, in particular the region spanning amino
acids 74 to 82, plays a role in the import of this protein to the
nucleus.


View larger version (74K):
[in this window]
[in a new window]
|
FIG. 5.
Subcellular localization of Vpx. vTF7-3 infected HeLa
cells were transfected with wild-type and mutant Vpx expression
plasmids. Twenty-four hours following transfection, the expressed Vpx
proteins were detected by indirect immunofluorescence with an anti-Vpx
monoclonal antibody (74) followed by an anti-mouse
FITC-conjugated secondary antibody. (a) Localization of Vpx; (b)
staining of cytoplasmic (red) and nuclear (blue) compartments with
Texas red-phalloidin and DAPI, respectively; (c) superimposition of
images shown in panels a and b for each row.
|
|
Signal-mediated nuclear import of Vpx.
Some proteins with
molecular masses of less than 40 kDa can enter the nucleus by passive
diffusion rather than by a signal-mediated process. To distinguish
between these two possibilities, we evaluated the import activities of
Vpx in the context of a chimeric protein designed to exceed the
diffusion limit of the nuclear pore (23, 24, 50).
Wild-type Vpx protein (18 kDa) was expressed as a fusion protein with
the 28-kDa GFP and analyzed for nuclear localization in transfected
HeLa cells (Fig. 6A). We
selected GFP as a fusion partner because the fusion protein can be
directly visualized in living cells without antibody staining. Further,
GFP is known to localize to the nucleus when attached to a functional
NLS (64). As shown in Fig. 6B (second row), most of the
GFP-Vpx fusion protein accumulated on the inside of the nuclear
membrane and the nuclear interior (as demonstrated by costaining of the
nuclear membrane with an antibody specific for the nucleoporin protein
p62), although some of the fusion protein was also visible on the
cytoplasmic face of the nuclear membrane. By contrast, GFP alone was
distributed throughout the cytoplasm and the nucleus (Fig. 6B, top
row). Importantly, Western blot analysis of whole-cell lysates
confirmed that the fusion protein had the appropriate predicted
molecular mass (46 kDa) (Fig. 6C, lane 2). Thus, as reported previously
(54, 72), Vpx appears to possess a specific signal that
mediates its nuclear uptake.



View larger version (91K):
[in this window]
[in a new window]
|
FIG. 6.
Construction, subcellular localization, expression and
packaging of GFP-Vpx fusion proteins. (A) Schematic representation of
GFP-Vpx fusion proteins. (B) Subcellular localization of GFP-Vpx fusion
proteins in HeLa cells (see Results for details). Subpanels: a, the
nuclear membrane was visualized by indirect immunofluorescence using a
nucleoporin p62 specific polyclonal antibody, followed by a Texas
red-conjugated goat anti-rabbit secondary antibody (red), and DAPI was
used for nuclear staining (blue); b, the GFP signal was used to
localize the GFP-Vpx fusion proteins; c, superimposition of images
shown in subpanels a and b for each row. (C) Expression of GFP-Vpx
fusion proteins. 293T cells were transfected with various GFP-Vpx
expression plasmids. Lysates of transfected cells were prepared 48 h after transfection and analyzed for fusion protein content by Western
blot analysis using an anti-GFP antibody. (D) Packaging of GFP-Vpx
fusion proteins. Expression plasmids were cotransfected with the PBj1.9
Vpx proviral clone X2, and virus particles were
concentrated from culture supernatants by ultracentrifugation through a
20% sucrose cushion, solubilized in gel loading buffer, and analyzed
for protein content by Western blot analysis using Vpx (top)- and Gag
(bottom)-specific monoclonal antibodies. Arrows indicate proteins with
Vpx reactivity. Lane 1, wild-type Vpx protein (18 kDa); lane 2, negative (GFP) control; lane 3, full-length GFP-Vpx fusion protein (46 kDa) as well as two smaller proteins (38 kDa and 20 kDa, respectively)
likely representing protease cleavage products; lane 4, lack of
GFP-Vpx1-63 packaging; lane 5, GFP-Vpx64-112 fusion protein (38 kDa).
|
|
Vpx amino acids 60 to 85 are sufficient to mediate transport of a
heterologous protein (GFP) to the nucleus.
Using additional GFP
fusion constructs, the role of the carboxyl-terminal half of Vpx in
nuclear localization was further examined. First, 49 amino acids from
the carboxyl terminus were deleted and the remaining 63 amino acids of
Vpx were fused to GFP (Fig. 6A). This GFP-Vpx1-63 construct was then
transfected into HeLa cells. As shown in Fig. 6B (third row), this
fusion protein yielded a diffuse staining pattern very similar to that observed for GFP alone. By contrast, fusion of GFP to the C-terminal half of Vpx (GFP-Vpx64-112) resulted in strong nuclear staining with
no reactivity detected in the cytoplasm (Fig. 6B, fourth row). As shown
by costaining with the nucleoporin p62 antibody, most of the
GFP-Vpx64-112 fusion protein was concentrated on the inside of the
nuclear membrane, similar to full-length Vpx. However, some staining
was also seen within the nucleus, suggesting that the Vpx64-112
fragment facilitated the transport of the GFP protein to and through
the nuclear membrane. The same observations were made when GFP was
linked to an even shorter fragment that spanned the evolutionarily most
highly conserved protein domain (aa 60 to 85) of Vpx. Again,
GFP-Vpx60-85 localized both to the inside of the nuclear membrane and
to the nuclear interior (Fig. 6B, bottom row). These results indicate
that Vpx amino acids 60 to 85 are sufficient to mediate the nuclear
import of a heterologous protein.
Finally, to determine the minimal virion packaging domain of Vpx, we
cotransfected the GFP-Vpx, GFP-Vpx1-63, GFP-Vpx64-112,
and
GFP-Vpx60-85 expression plasmids with a PBj1.9 Vpx

proviral clone and examined the resulting virions by Western
blot
analysis. The PBj1.9 wild-type construct was also transfected
alone as
a control. Anti-Vpx antiserum detected the 18-kDa (native)
Vpx protein
in virions derived from the SIVsm(PBj1.9) wild-type
construct. Strongly
Vpx-reactive proteins, 46 and 38 kDa in size,
were also detected in
virions derived by coexpression of PBj1.9
Vpx

with
GFP-Vpx and GFP-Vpx64-112 constructs, respectively (Fig.
6D, lanes 3 and 5). However, fusion proteins GFP-Vpx1-63 (Fig.
6D, lane 4) and
GFP-Vpx60-85 (data not shown) were not incorporated
into virus
particles. These results suggest that the N-terminal
half of Vpx is not
involved in virion incorporation. Moreover,
the Vpx60-85 fragment was
not sufficient to package a heterologous
protein into virus particles,
although it contained all residues
shown to be critical for virion
incorporation by site-directed
mutagenesis (Fig.
3).
 |
DISCUSSION |
Vpx has two distinct localization properties that direct it
either to the nuclear membrane and the interior of the nucleus (72) or, in association with Gag, to budding virus
particles at the plasma membrane (1, 29, 33, 53, 74, 76).
These two opposite Vpx localizations must be mediated through different protein-protein interactions. In order to identify the amino acid residues and/or motifs involved in these processes, we introduced a
number of point mutations into Vpx domains that we found to be highly
conserved among divergent isolates of HIV-2, SIVsm/SIVmac, and SIVrcm,
as well as between the Vpx proteins of these viruses and the Vpr
protein of HIV-1 (Fig. 1). Our data indicate that the carboxyl-terminal
half of Vpx encompasses determinants for both virion incorporation and
nuclear localization (Fig. 7), as supported by the following: (i) mutation of two highly conserved residues, L74 and I75, impaired both virion incorporation and nuclear
localization of Vpx; (ii) substitution of conserved H82, G86, C87,
P103, and P106 residues impaired Vpx nuclear localization as well as
replication of mutant virus in macaque macrophages; (iii) mutations of
conserved Y66, Y69, and Y71 residues impaired packaging of Vpx into
virus particles; (iv) a mutation at E30 (predicted to disrupt an
N-terminal
-helix) had no effect on either virion incorporation or
nuclear localization of Vpx; and (v) a Vpx fragment of 26 amino acids
(aa 60 to 85) was found to be sufficient to mediate the transport of a
heterologous protein (GFP) to the nucleus.

View larger version (7K):
[in this window]
[in a new window]
|
FIG. 7.
Mutational analysis of the C-terminal half of Vpx. The
asterisks indicate amino acid residues that are absolutely essential
for the functions indicated; the brackets denote residues that (when
mutated) cause some functional impairment. The horizontal bar
highlights the fragment of Vpx that is sufficient to mediate the
transport of a heterologous protein (GFP) to the nucleus.
|
|
Vpx mutants Y66,69,71A and LI74,75S resulted in a total abrogation of
Vpx packaging, suggesting that the integrity of the putative helical
domain II (aa 71 to 82) is important for Gag interaction.
Interestingly, there are two
-helical domains in HIV-1 Vpr, both of
which are important for virion incorporation (38, 39, 41, 63, 73,
75). However, this seems not to be the case for Vpx, as the
N-terminal half of the protein is clearly dispensable for packaging.
The E30P mutant which was designed to cause disruption of helix I
packaged at wild-type levels, and the N-terminal half of Vpx failed to
mediate virion incorporation of a GFP fusion protein. By contrast, the
GFP-Vpx64-112 fusion protein did package, indicating that the
C-terminal 49 amino acids are sufficient to target a heterologous
protein to the virus particle. Thus, the packaging domain must reside
in the C-terminal half of Vpx, although its precise boundaries remain to be determined.
A recent study reported that deletion of amino acids 78 to 80 and 82 to
87 abolished the incorporation of Vpx into virus particles (55). Analyzing substitution mutations between
amino acid position 82 and 87, we observed wild-type packaging
(Fig. 3B). Hence, the reported impairment of virion incorporation of
the latter mutant may have been due to altered protein
stability and/or an impaired protein conformation. Deletion mutant
Vpx78-80 likely disrupted the putative helical domain II which we found
to be critical for packaging. Interestingly, the Vpx60-85 fragment,
which spans this region, was not sufficient to mediate the packaging of
a heterologous protein. Thus, the minimal packaging domain of Vpx must
extend beyond the putative helix II, although it probably does not
require the entire C terminus, since deletion of the proline-rich
domain does not abrogate Vpx packaging (54). Given their
absolute requirement for Vpx packaging, Y66,69,71 as well as L74 and
I75 residues in helical domain II may be directly involved in Vpx-Gag
interactions. Tyrosine residues are frequently involved in
phosphorylation and protein-protein interactions in signal transduction
pathways (3, 32, 57). It will be interesting to determine
whether phosphorylation of the conserved tyrosine motif (YXXYXY) in Vpx
is involved in the association of Vpx to Gag.
We also assessed the replication potential of vpx mutant
SIVsm in dividing and nondividing cells. Viruses that
contained mutations at positions Y66,69,71, LI74,75, H82,
GC86,87, and P103,106 either failed to replicate or grew only very
poorly in macaque macrophages (Fig. 4). Vpx Y66,69,71A and LI74,75S
mutants are readily explained since these fail to package into virus
particles. However, the other mutant proteins were present in
virions at near-wild-type levels and thus likely affected the nuclear
import properties of the viral PICs, either directly or indirectly. For
example, SIVsm virions encoding the Vpx H82S mutation replicated in
macaque macrophages as poorly as virions that contained no Vpx at all (Fig. 4). While these results do not formally prove that the H82S mutation rendered the corresponding SIVsm PIC nuclear import defective, the complete loss of nuclear targeting of the H82S mutant protein is
consistent with this explanation (Fig. 5, row 5). Of course, other PIC
components such as the viral integrase are likely to also play a role
in PIC nuclear transport. Thus, future studies will need to examine to
what extent nuclear import properties of Vpx govern nuclear import
properties of the viral PIC. The Vpx mutant constructs described here
should be useful in guiding such studies.
We also identified a 26-amino-acid domain (aa 60 to 85) in the C
terminus of Vpx which appears to encode a novel nuclear targeting signal (Fig. 7). This stretch of amino acids is conserved among all Vpx
proteins identified to date, including the highly divergent SIVrcm Vpx
protein (Fig. 1). Recently, Pancio and coworkers reported that deletion
of the C-terminal proline-rich domain (aa 102 to 112) of Vpx resulted
in a block of nuclear localization of HIV-2 DNA, thus implicating this
particular domain in the nuclear transport of the HIV-2 PIC
(54). Our 26-amino-acid nuclear targeting domain lies
upstream of this proline-rich region, raising the possibility that Vpx,
like HIV-1 Vpr, contains two independent nuclear targeting domains.
Alternatively, deletion of the proline-rich domain may have impaired
Vpx function indirectly by changing protein structure or conformation.
To distinguish between these two possibilities, it will be important to
test whether Vpx86-112, like Vpx60-85, can mediate the nuclear
transport of a heterologous fusion partner. Nevertheless, we also
observed that point mutations in the proline rich domain (Vpx
P103,106S) reduced viral replication in macrophages (Fig. 4) and
impaired nuclear localization of the corresponding protein (Fig. 5,
bottom row). This finding is consistent with an involvement of the
proline-rich Vpx C terminus in PIC nuclear import. However, the
observed impairment was much less severe than that caused by mutations
in the upstream nuclear localization domain, suggesting that the
proline-rich domain does not constitute the major nuclear import
signal. The lack of a proline-rich domain in the SIVrcm Vpx protein
also supports this notion.
The 26-amino-acid domain of Vpx that mediated nuclear targeting of GFP
is different not only from classical NLSs (lysine rich) (10) but also from recently identified M9 and hnRNP K
protein nuclear shuttling (45, 46, 49) sequences as well
as arginine-rich NLS domains (52, 68, 70, 71).
Accumulation in the nuclear membrane is not an attribute ordinarily
associated with NLSs, although the import factor importin
localizes
to the nuclear membrane (23). It is thus possible that Vpx
plays a primary role in the docking process of the viral PIC to the
nuclear membrane rather than in more distal nuclear import events.
Further studies of Vpx and other PIC components will be important to
define the mechanism(s) by which HIV-2/SIV preintegration complexes
move from one side of the nuclear pore to the other. Since there is presently little consensus concerning the mechanism of nuclear import
of lentiviral PICs, the evolutionarily highly conserved 26-amino-acid
Vpx nuclear targeting signal identified here is likely to provide a new
tool to study the mechanisms that govern early steps in primate
lentiviral replication.
 |
ACKNOWLEDGMENTS |
We thank Wendy Abbott and Jennifer Wilson for artwork and
secretarial assistance.
This work was supported by grants from the National Institutes of
Health (POI AI41215 and ROI AI 34748 to B.H.H.) and the Howard Hughes
Medical Institute.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Departments of
Medicine and Microbiology, University of Alabama at Birmingham, LHRB 613, 701 19th St. South, Birmingham, AL 35294. Phone: (205) 934-0412. Fax: (205) 934-1580. E-mail: bhahn{at}uab.edu.
Laboratory of Molecular Virology, Center for DNA Fingerprinting and
Diagnostics, Nacharam, Hyderabad 500 076, India.
 |
REFERENCES |
| 1.
|
Accola, M. A.,
A. A. Bukovsky,
M. S. Jones, and H. G. Göttlinger.
1999.
A conserved dileucine-containing motif in p6gag governs the particle association of Vpx and Vpr of simian immunodeficiency viruses SIVmac and SIVagm.
J. Virol.
73:9992-9999[Abstract/Free Full Text].
|
| 2.
|
Bonifaci, N.,
J. Moroianu,
A. Radu, and G. Blobel.
1997.
Karyopherin beta2 mediates nuclear import of a mRNA binding protein.
Proc. Natl. Acad. Sci. USA
94:5055-5060[Abstract/Free Full Text].
|
| 3.
|
Bresnahan, P. A.,
W. Yonemoto, and W. C. Greene.
1999.
Cutting edge: SIV Nef protein utilizes both leucine- and tyrosine-based protein sorting pathways for down-regulation of CD4.
J. Immunol.
163:2977-2981[Abstract/Free Full Text].
|
| 4.
|
Bukrinsky, M. I.,
S. Haggerty,
M. P. Dempsey,
N. Sharova,
A. Adzhubel,
L. Spitz,
P. Lewis,
D. Goldfarb,
M. Emerman, and M. Stevenson.
1993.
A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells.
Nature
365:666-669[CrossRef][Medline].
|
| 5.
|
Chou, P. Y., and G. D. Fasman.
1978.
Prediction of the secondary structure of proteins from their amino acid sequence.
Adv. Enzymol. Relat. Areas Mol. Biol.
47:45-48[Medline].
|
| 6.
|
Corbett, A. H., and P. A. Silver.
1997.
Nucleocytoplasmic transport of macromolecules.
Microbiol. Mol. Biol. Rev.
61:193-211[Abstract].
|
| 7.
|
Cullen, B. R.
1998.
HIV-1 auxiliary proteins: making connections in a dying cell.
Cell
93:685-692[CrossRef][Medline].
|
| 8.
|
Dewhurst, S.,
J. E. Embretson,
D. C. Anderson,
J. I. Mullins, and P. N. Fultz.
1990.
Sequence analysis and acute pathogenicity of molecularly cloned SIVSMM-PBj14.
Nature
345:636-640[CrossRef][Medline].
|
| 9.
|
Di Marzio, P.,
S. Choe,
M. Ebright,
R. Knoblauch, and N. R. Landau.
1995.
Mutational analysis of cell cycle arrest, nuclear localization, and virion packaging of human immunodeficiency virus type 1 Vpr.
J. Virol.
69:7909-7916[Abstract].
|
| 10.
|
Dingwall, C., and R. A. Laskey.
1991.
Nuclear targeting sequences a consensus?
Trends Biochem. Sci.
16:478-481[CrossRef][Medline].
|
| 11.
|
Emerman, M.
1996.
HIV-1, Vpr and the cell cycle.
Curr. Biol.
6:1096-1103[CrossRef][Medline].
|
| 12.
|
Fletcher, T. M.,
B. Brichacek,
N. Sharova,
M. A. Newman,
G. Stivahtis,
P. M. Sharp,
M. Emerman,
B. H. Hahn, and M. Stevenson.
1996.
Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIV(SM).
EMBO J.
15:6155-6165[Medline].
|
| 13.
|
Fouchier, R. A.,
B. E. Meyer,
J. H. Simon,
U. Fischer,
A. V. Albright,
F. Gonzalez-Scarano, and M. H. Malim.
1998.
Interaction of the human immunodeficiency virus type 1 Vpr protein with the nuclear pore complex.
J. Virol.
72:6004-6013[Abstract/Free Full Text].
|
| 14.
|
Fouchier, R. A.,
B. E. Meyer,
J. H. Simon,
U. Fischer, and M. H. Malim.
1997.
HIV-1 infection of non-dividing cells: evidence that the amino-terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import.
EMBO J.
16:4531-4539[CrossRef][Medline].
|
| 15.
|
Fridell, R. A.,
R. Truant,
L. Thorne,
R. E. Benson, and B. R. Cullen.
1997.
Nuclear import of hnRNP A1 is mediated by a novel cellular cofactor related to karyopherin-beta.
J. Cell Sci.
110:1325-1331[Abstract].
|
| 16.
|
Fuerst, T. R.,
P. L. Earl, and B. Moss.
1987.
Use of a hybrid vaccinia virus-T7 RNA polymerase system for expression of target genes.
Mol. Cell. Biol.
7:2538-2544[Abstract/Free Full Text].
|
| 17.
|
Gallay, P.,
T. Hope,
D. Chin, and D. Trono.
1997.
HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway.
Proc. Natl. Acad. Sci. USA
94:9825-9830[Abstract/Free Full Text].
|
| 18.
|
Gallay, P.,
V. Stitt,
C. Mundy,
M. Oettinger, and D. Trono.
1996.
Role of the karyopherin pathway in human immunodeficiency virus type 1 nuclear import.
J. Virol.
70:1027-1032[Abstract].
|
| 19.
|
Gallay, P.,
S. Swingler,
C. Aiken, and D. Trono.
1995.
HIV-1 infection of nondividing cells: C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulator.
Cell
80:379-388[CrossRef][Medline].
|
| 20.
|
Garnier, L.,
J. W. Wills,
M. F. Verderame, and M. Sudol.
1996.
WW domains and retrovirus budding.
Nature
381:744-745[CrossRef][Medline].
|
| 21.
|
Georges-Courbot, M. C.,
C. Y. Lu,
M. Makuwa,
P. Telfer,
R. Onanga,
G. Dubreuil,
Z. Chen,
S. M. Smith,
A. Georges,
F. Gao,
B. H. Hahn, and P. A. Marx.
1998.
Natural infection of a household pet red-capped mangabey (Cercocebus torquatus torquatus) with a new simian immunodeficiency virus.
J. Virol.
72:600-608[Abstract/Free Full Text].
|
| 22.
|
Goh, W. C.,
M. E. Rogel,
C. M. Kinsey,
S. F. Michael,
P. N. Fultz,
M. A. Nowak,
B. H. Hahn, and M. Emerman.
1998.
HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo.
Nat. Med.
4:65-71[CrossRef][Medline].
|
| 23.
|
Gorlich, D.
1997.
Nuclear protein import.
Curr. Opin. Cell. Biol.
9:412-419[CrossRef][Medline].
|
| 24.
|
Gorlich, D., and I. W. Mattaj.
1996.
Nucleocytoplasmic transport.
Science
271:1513-1518[Abstract].
|
| 25.
|
Gorlich, D.,
N. Pante,
U. Kutay,
U. Aebi, and F. R. Bischoff.
1996.
Identification of different roles for RanGDP and RanGTP in nuclear protein import.
EMBO J.
15:5584-5594[Medline].
|
| 26.
|
Hahn, B. H.,
G. M. Shaw,
K. M. De Cock, and P. M. Sharp.
2000.
AIDS as a zoonosis: scientific and public health implications.
Science
287:607-614[Abstract/Free Full Text].
|
| 27.
|
Harty, R. N.,
J. Paragas,
M. Sudol, and P. Palese.
1999.
A proline-rich motif within the matrix protein of vesicular stomatitis virus and rabies virus interacts with WW domains of cellular proteins: implications for viral budding.
J. Virol.
73:2921-2929[Abstract/Free Full Text].
|
| 28.
|
Heinzinger, N. K.,
M. I. Bukinsky,
S. A. Haggerty,
A. M. Ragland,
V. Kewalramani,
M. A. Lee,
H. E. Gendelman,
L. Ratner,
M. Stevenson, and M. Emerman.
1994.
The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells.
Proc. Natl. Acad. Sci. USA
91:7311-7315[Abstract/Free Full Text].
|
| 29.
|
Henderson, L. E.,
R. C. Sowder,
T. D. Copeland,
R. E. Benveniste, and S. Oroszlan.
1988.
Isolation and characterization of a novel protein (X-ORF product) from SIV and HIV-2.
Science
241:199-201[Abstract/Free Full Text].
|
| 30.
|
Hirsch, V. M.,
M. E. Sharkey,
C. R. Brown,
B. Brichacek,
S. Goldstein,
J. Wakefield,
R. Byrum,
W. R. Elkins,
B. H. Hahn,
J. D. Lifson, and M. Stevenson.
1998.
Vpx is required for dissemination and pathogenesis of SIV(SM) PBj: evidence of macrophage-dependent viral amplification.
Nat. Med.
4:1401-1408[CrossRef][Medline].
|
| 31.
|
Jenkins, Y.,
M. McEntee,
K. Weis, and W. C. Greene.
1998.
Characterization of HIV-1 vpr nuclear import: analysis of signals and pathways.
J. Cell. Biol.
143:875-885[Abstract/Free Full Text].
|
| 32.
|
Kang, H.,
C. Freund,
J. S. Duke-Cohan,
A. Musacchio,
G. Wagner, and C. E. Rudd.
2000.
SH3 domain recognition of a proline-independent tyrosine-based RkxxYxxY motif in immune cell adaptor SKAP55.
EMBO J.
19:2889-2899[CrossRef][Medline].
|
| 33.
|
Kappes, J. C.,
C. D. Morrow,
S.-W. Lee,
B. A. Jameson,
S. B. H. Kent,
L. E. Hood,
G. M. Shaw, and B. H. Hahn.
1989.
Identification of a novel retroviral gene unique to human immunodeficiency virus type 2 and simian immunodeficiency virus SIVMAC.
J. Virol.
62:3501-3505.
|
| 34.
|
Kappes, J. C.,
J. S. Parkin,
J. A. Conway,
J. Kim,
C. G. Brouillette,
G. M. Shaw, and B. H. Hahn.
1993.
Intracellular transport and virion incorporation of vpx requires interaction with other virus type-specific components.
Virology
193:222-233[CrossRef][Medline].
|
| 35.
|
Kewalramani, V. N., and M. Emerman.
1996.
Vpx association with mature core structure of HIV-2.
Virology
218:159-168[CrossRef][Medline].
|
| 36.
|
LaCasse, E. C., and Y. A. LaFebvre.
1995.
Nuclear localization signals overlap DNA- or RNA-binding domains in nucleic-acid binding proteins.
Nucleic Acids Res.
23:1647-1656[Free Full Text].
|
| 37.
|
Lewis, P. F., and M. Emerman.
1994.
Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus.
J. Virol.
68:510-516[Abstract/Free Full Text].
|
| 38.
|
Lu, Y. L.,
R. P. Bennett,
J. W. Wills,
R. Gorelick, and L. Ratner.
1995.
A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles.
J. Virol.
69:6873-6879[Abstract].
|
| 39.
|
Lu, Y. L.,
P. Spearman, and L. Ratner.
1993.
Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions.
J. Virol.
67:6542-6550[Abstract/Free Full Text].
|
| 40.
|
Macreadie, I. G.,
L. A. Castelli,
D. R. Hewish,
A. Kirkpatrick,
A. C. Ward, and A. A. Azad.
1995.
A domain of human immunodeficiency virus type 1 Vpr containing repeated H(S/F)RIG amino acid motifs causes cell growth arrest and structural defects.
Proc. Natl. Acad. Sci. USA
92:2770-2774[Abstract/Free Full Text].
|
| 41.
|
Mahalingam, S.,
V. Ayyavoo,
M. Patel,
T. Kieber-Emmons, and D. B. Weiner.
1997.
Nuclear import, virion incorporation, and cell cycle arrest/differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr.
J. Virol.
71:6339-6347[Abstract].
|
| 42.
|
Mahalingam, S.,
S. A. Khan,
M. A. Jabbar,
C. E. Monken,
R. G. Collman, and A. Srinivasan.
1995.
Identification of residues in the N-terminal acidic domain of HIV-1 Vpr essential for virion incorporation.
Virology
207:297-302[CrossRef][Medline].
|
| 43.
|
Melchior, F., and L. Gerace.
1998.
Two-way trafficking with Ran.
Trends Cell Biol.
8:175-179[CrossRef][Medline].
|
| 44.
|
Melchior, F.,
B. Paschal,
J. Evans, and L. Gerace.
1993.
Inhibition of nuclear protein import by nonhydrolyzable analogues of GTP and identification of the small GTPase Ran/TC4 as an essential transport factor.
J. Cell Biol.
123:1649-1659[Abstract/Free Full Text].
|
| 45.
|
Michael, W. M.,
P. S. Eder, and G. Dreyfuss.
1997.
The K nuclear shuttling domain: a novel signal for nuclear import and nuclear export in the hnRNP K protein.
EMBO J.
16:3587-3598[CrossRef][Medline].
|
| 46.
|
Michael, W. M.,
H. Siomi,
M. Choi,
S. Pinol-Roma,
S. Nakielny,
Q. Liu, and G. Dreyfuss.
1995.
Signal sequences that target nuclear import and nuclear export of pre- mRNA-binding proteins.
Cold Spring Harbor Symp. Quant. Biol.
60:663-668[Abstract/Free Full Text].
|
| 47.
|
Michaud, N., and D. Goldfarb.
1992.
Microinjected U snRNAs are imported to oocyte nuclei via the nuclear pore complex by three distinguishable targeting pathways.
J. Cell Biol.
116:851-861[Abstract/Free Full Text].
|
| 48.
|
Moore, M. S., and G. Blobel.
1994.
Purification of a Ran-interacting protein that is required for protein import into the nucleus.
Proc. Natl. Acad. Sci. USA
91:10212-10216[Abstract/Free Full Text].
|
| 49.
|
Nakielny, S., and G. Dreyfuss.
1999.
Transport of proteins and RNAs in and out of the nucleus.
Cell
99:677-690[CrossRef][Medline].
|
| 50.
|
Nigg, E. A.
1997.
Nucleocytoplasmic transport: signals, mechanisms and regulation.
Nature
386:779-787[CrossRef][Medline].
|
| 51.
|
Ohno, M.,
M. Fornerod, and I. W. Mattaj.
1998.
Nucleocytoplasmic transport: the last 200 nanometers.
Cell
92:327-336[CrossRef][Medline].
|
| 52.
|
Palmeri, D., and M. H. Malim.
1999.
Importin beta can mediate the nuclear import of an arginine-rich nuclear localization signal in the absence of importin alpha.
Mol. Cell. Biol.
19:1218-1225[Abstract/Free Full Text].
|
| 53.
|
Pancio, H. A., and L. Ratner.
1998.
Human immunodeficiency virus type 2 Vpx-Gag interaction.
J. Virol.
72:5271-5275[Abstract/Free Full Text].
|
| 54.
|
Pancio, H. A.,
N. Vander Heyden, and L. Ratner.
2000.
The C-terminal proline-rich tail of human immunodeficiency virus type 2 vpx is necessary for nuclear localization of the viral preintegration complex in nondividing cells.
J. Virol.
74:6162-6167[Abstract/Free Full Text].
|
| 55.
|
Park, I. W., and J. Sodroski.
1995.
Amino acid sequence requirements for the incorporation of the Vpx protein of simian immunodeficiency virus into virion particles.
J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.
10:506-510[Medline].
|
| 56.
|
Paxton, W.,
R. I. Connor, and N. R. Landau.
1993.
Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis.
J. Virol.
67:7229-7237[Abstract/Free Full Text].
|
| 57.
|
Piguet, V.,
Y. L. Chen,
A. Mangasarian,
M. Foti,
J. L. Carpentier, and D. Trono.
1998.
Mechanism of Nef-induced CD4 endocytosis: Nef connects CD4 with the mu chain of adaptor complexes.
EMBO J.
17:2472-2481[CrossRef][Medline].
|
| 58.
|
Pollard, V. W.,
W. M. Michael,
S. Nakielny,
M. C. Siomi,
F. Wang, and G. Dreyfuss.
1996.
A novel receptor-mediated nuclear protein import pathway.
Cell
86:985-994[CrossRef][Medline].
|
| 59.
|
Popov, S.,
M. Rexach,
G. Zybarth,
N. Reiling,
M. A. Lee,
L. Ratner,
C. M. Lane,
M. S. Moore,
G. Blobel, and M. Bukrinsky.
1998.
Viral protein R regulates nuclear import of the HIV-1 pre-integration complex.
EMBO J.
17:909-917[CrossRef][Medline].
|
| 60.
|
Radu, A.,
G. Blobel, and M. S. Moore.
1995.
Identification of a protein complex that is required for nuclear protein import and mediates docking of import substrate to distinct nucleoporins.
Proc. Natl. Acad. Sci. USA
92:1769-1773[Abstract/Free Full Text].
|
| 61.
|
Re, F.,
D. Braaten,
E. K. Franke, and J. Luban.
1995.
Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B.
J. Virol.
69:6859-6864[Abstract].
|
| 62.
|
Rogel, M. E.,
L. I. Wu, and M. Emerman.
1995.
The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection.
J. Virol.
69:882-888[Abstract].
|
| 63.
|
Schuler, W.,
K. Wecker,
H. de Rocquigny,
Y. Baudat,
J. Sire, and B. P. Roques.
1999.
NMR structure of the (52-96) C-terminal domain of the HIV-1 regulatory protein Vpr: molecular insights into its biological functions.
J. Mol. Biol.
285:2105-2117[CrossRef][Medline].
|
| 64.
|
Stauber, R. H., and G. N. Pavlakis.
1998.
Intracellular trafficking and interactions of the HIV-1 Tat protein.
Virology
252:126-136[CrossRef][Medline].
|
| 65.
|
Stivahtis, G. L.,
M. A. Soares,
M. A. Vodicka,
B. H. Hahn, and M. Emerman.
1997.
Conservation and host specificity of Vpr-mediated cell cycle arrest suggest a fundamental role in primate lentivirus evolution and biology.
J. Virol.
71:4331-4338[Abstract].
|
| 66.
|
Subbramanian, R. A.,
X. J. Yao,
H. Dilhuydy,
N. Rougeau,
D. Bergeron,
Y. Robitaille, and E. A. Cohen.
1998.
Human immunodeficiency virus type 1 Vpr localization: nuclear transport of a viral protein modulated by a putative amphipathic helical structure and its relevance to biological activity.
J. Mol. Biol.
278:13-30[CrossRef][Medline].
|
| 67.
|
Tacke, E.,
J. Schmitz,
D. Prufer, and W. Rohde.
1993.
Mutational analysis of the nucleic acid-binding 17 kDa phosphoprotein of potato leafroll luteovirus identifies an amphipathic alpha-helix as the domain for protein/protein interactions.
Virology
197:274-282[CrossRef][Medline].
|
| 68.
|
Tiganis, T.,
A. J. Flint,
S. A. Adam, and N. K. Tonks.
1997.
Association of the T-cell protein tyrosine phosphatase with nuclear import factor p97.
J. Biol. Chem.
272:21548-21557[Abstract/Free Full Text].
|
| 69.
|
Trono, D.
1998.
When accessories turn out to be essential.
Nat. Med.
4:1368-1369[CrossRef][Medline].
|
| 70.
|
Truant, R., and B. R. Cullen.
1999.
The arginine-rich domains present in human immunodeficiency virus type 1 Tat and Rev function as direct importin beta-dependent nuclear localization signals.
Mol. Cell. Biol.
19:1210-1217[Abstract/Free Full Text].
|
| 71.
|
Truant, R.,
R. A. Fridell,
R. E. Benson,
H. Bogerd, and B. R. Cullen.
1998.
Identification and functional characterization of a novel nuclear localization signal present in the yeast Nab2 poly(A)+ RNA binding protein.
Mol. Cell. Biol.
18:1449-1458[Abstract/Free Full Text].
|
| 72.
|
Vodicka, M. A.,
D. M. Koepp,
P. A. Silver, and M. Emerman.
1998.
HIV-1 Vpr interacts with the nuclear transport pathway to promote macrophage infection.
Genes Dev.
12:175-185[Abstract/Free Full Text].
|
| 73.
|
Wecker, K., and B. P. Roques.
1999.
NMR structure of the (1-51) N-terminal domain of the HIV-1 regulatory protein Vpr.
Eur. J. Biochem.
266:359-369[Medline].
|
| 74.
|
Wu, X.,
J. A. Conway,
J. Kim, and J. C. Kappes.
1994.
Localization of the Vpx packaging signal within the C terminus of the human immunodeficiency virus type 2 Gag precursor protein.
J. Virol.
68:6161-6169[Abstract/Free Full Text].
|
| 75.
|
Yao, X.-J.,
R. A. Subbramanian,
N. Rougeau,
F. Boisvert,
D. Bergeron, and E. A. Cohen.
1995.
Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation.
J. Virol.
69:7032-7044[Abstract].
|
| 76.
|
Yu, X. F.,
S. Ito,
M. Essex, and T. H. Lee.
1988.
A naturally immunogenic virion-associated protein specific for HIV-2 and SIV.
Nature
335:262-265[CrossRef][Medline].
|
| 77.
|
Zhao, L. J.,
S. Mukherjee, and O. Narayan.
1994.
Biochemical mechanism of HIV-1 Vpr function. Specific interaction with a cellular protein.
J. Biol. Chem.
269:15577-15582[Abstract/Free Full Text].
|
| 78.
|
Zhou, Y.,
Y. Lu, and L. Ratner.
1998.
Arginine residues in the C-terminus of HIV-1 Vpr are important for nuclear localization and cell cycle arrest.
Virology
242:414-424[CrossRef][Medline].
|
Journal of Virology, January 2001, p. 362-374, Vol. 75, No. 1
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.1.362-374.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Bergamaschi, A., Ayinde, D., David, A., Le Rouzic, E., Morel, M., Collin, G., Descamps, D., Damond, F., Brun-Vezinet, F., Nisole, S., Margottin-Goguet, F., Pancino, G., Transy, C.
(2009). The Human Immunodeficiency Virus Type 2 Vpx Protein Usurps the CUL4A-DDB1DCAF1 Ubiquitin Ligase To Overcome a Postentry Block in Macrophage Infection. J. Virol.
83: 4854-4860
[Abstract]
[Full Text]
-
Goujon, C., Arfi, V., Pertel, T., Luban, J., Lienard, J., Rigal, D., Darlix, J.-L., Cimarelli, A.
(2008). Characterization of Simian Immunodeficiency Virus SIVSM/Human Immunodeficiency Virus Type 2 Vpx Function in Human Myeloid Cells. J. Virol.
82: 12335-12345
[Abstract]
[Full Text]
-
Cheng, X., Belshan, M., Ratner, L.
(2008). Hsp40 Facilitates Nuclear Import of the Human Immunodeficiency Virus Type 2 Vpx-Mediated Preintegration Complex. J. Virol.
82: 1229-1237
[Abstract]
[Full Text]
-
Singhal, P. K., Rajendra Kumar, P., Subba Rao, M. R. K., Mahalingam, S.
(2006). Nuclear Export of Simian Immunodeficiency Virus Vpx Protein. J. Virol.
80: 12271-12282
[Abstract]
[Full Text]
-
Singhal, P. K., Kumar, P. R., Rao, M. R. K. S., Kyasani, M., Mahalingam, S.
(2006). Simian Immunodeficiency Virus Vpx Is Imported into the Nucleus via Importin Alpha-Dependent and -Independent Pathways. J. Virol.
80: 526-536
[Abstract]
[Full Text]
-
Rajendra Kumar, P., Singhal, P. K., Subba Rao, M. R. K., Mahalingam, S.
(2005). Phosphorylation by MAPK Regulates Simian Immunodeficiency Virus Vpx Protein Nuclear Import and Virus Infectivity. J. Biol. Chem.
280: 8553-8563
[Abstract]
[Full Text]
-
Mueller, S. M., Jung, R., Weiler, S., Lang, S. M.
(2004). Vpx proteins of SIVmac239 and HIV-2ROD interact with the cytoskeletal protein {alpha}-actinin 1. J. Gen. Virol.
85: 3291-3303
[Abstract]
[Full Text]
-
Zander, K., Sherman, M. P., Tessmer, U., Bruns, K., Wray, V., Prechtel, A. T., Schubert, E., Henklein, P., Luban, J., Neidleman, J., Greene, W. C., Schubert, U.
(2003). Cyclophilin A Interacts with HIV-1 Vpr and Is Required for Its Functional Expression. J. Biol. Chem.
278: 43202-43213
[Abstract]
[Full Text]
-
Hu, J., Switzer, W. M., Foley, B. T., Robertson, D. L., Goeken, R. M., Korber, B. T., Hirsch, V. M., Beer, B. E.
(2003). Characterization and Comparison of Recombinant Simian Immunodeficiency Virus from Drill (Mandrillus leucophaeus) and Mandrill (Mandrillus sphinx) Isolates. J. Virol.
77: 4867-4880
[Abstract]
[Full Text]